Rhumbline Advisers Buys 2,436 Shares of MiMedx Group, Inc (NASDAQ:MDXG)

Rhumbline Advisers increased its stake in MiMedx Group, Inc (NASDAQ:MDXG) by 1.4% during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 177,156 shares of the company’s stock after purchasing an additional 2,436 shares during the period. Rhumbline Advisers owned approximately 0.12% of MiMedx Group worth $1,346,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also bought and sold shares of MDXG. Savant Capital LLC bought a new position in MiMedx Group during the fourth quarter valued at approximately $100,000. Van ECK Associates Corp bought a new position in MiMedx Group during the fourth quarter valued at approximately $40,000. Principal Financial Group Inc. grew its position in MiMedx Group by 8.5% during the fourth quarter. Principal Financial Group Inc. now owns 60,226 shares of the company’s stock valued at $579,000 after acquiring an additional 4,731 shares during the last quarter. New York State Common Retirement Fund grew its position in MiMedx Group by 93.0% during the fourth quarter. New York State Common Retirement Fund now owns 57,840 shares of the company’s stock valued at $556,000 after acquiring an additional 27,867 shares during the last quarter. Finally, Bank of New York Mellon Corp grew its position in MiMedx Group by 0.7% during the fourth quarter. Bank of New York Mellon Corp now owns 504,007 shares of the company’s stock valued at $4,849,000 after acquiring an additional 3,300 shares during the last quarter. 79.15% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other MiMedx Group news, CEO Joseph H. Capper purchased 200,000 shares of the company’s stock in a transaction that occurred on Friday, May 2nd. The stock was bought at an average price of $6.34 per share, with a total value of $1,268,000.00. Following the completion of the purchase, the chief executive officer now directly owns 529,530 shares of the company’s stock, valued at $3,357,220.20. The trade was a 60.69% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. 1.70% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have commented on MDXG shares. Cantor Fitzgerald reiterated an “overweight” rating and set a $13.00 price target on shares of MiMedx Group in a research report on Thursday, February 27th. Wall Street Zen upgraded shares of MiMedx Group from a “hold” rating to a “buy” rating in a research report on Friday, June 6th.

MiMedx Group Stock Performance

NASDAQ:MDXG opened at $5.90 on Thursday. The firm has a market cap of $871.43 million, a PE ratio of 21.85 and a beta of 1.82. MiMedx Group, Inc has a fifty-two week low of $5.47 and a fifty-two week high of $10.14. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.13 and a current ratio of 4.70. The business has a 50 day moving average price of $6.67 and a 200-day moving average price of $7.88.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings data on Wednesday, April 30th. The company reported $0.06 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.06. The firm had revenue of $88.21 million during the quarter, compared to analyst estimates of $86.32 million. MiMedx Group had a return on equity of 22.70% and a net margin of 11.40%. Equities research analysts predict that MiMedx Group, Inc will post 0.3 earnings per share for the current year.

MiMedx Group Company Profile

MiMedx Group, Inc develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue’s inherent biological properties and regulatory proteins.